Liang L - Search Results

1

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.

Desai J, Deva S, Lee JS, Lin CC, Yen CJ, Chao Y, Keam B, Jameson M, Hou MM, Kang YK, Markman B, Lu CH, Rau KM, Lee KH, Horvath L, Friedlander M, Hill A, Sandhu S, Barlow P, Wu CY, Zhang Y, Liang L, Wu J, Paton V, Millward M. Desai J, et al. Among authors: liang l. J Immunother Cancer. 2020 Jun;8(1):e000453. doi: 10.1136/jitc-2019-000453. J Immunother Cancer. 2020. PMID: 32540858 Free PMC article. Clinical Trial.

2

Evaluation of the EdgeSeq Precision Immuno-Oncology Panel for Gene Expression Profiling From Clinical Formalin-Fixed Paraffin-Embedded Tumor Specimens.

Shi Y, Ma X, Shen W, Liu T, Liang L, Liu S, Shen Z, Zhang Y, Zhang P. Shi Y, et al. Among authors: liang l. Front Cell Dev Biol. 2022 May 27;10:899353. doi: 10.3389/fcell.2022.899353. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35712667 Free PMC article.

3

Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors.

Ye D, Desai J, Shi J, Liu SM, Shen W, Liu T, Shi Y, Wang D, Liang L, Yang S, Ma X, Jin W, Zhang P, Huang R, Shen Z, Zhang Y, Wu YL. Ye D, et al. Among authors: liang l. Biomark Res. 2023 Mar 7;11(1):25. doi: 10.1186/s40364-023-00465-w. Biomark Res. 2023. PMID: 36879284 Free PMC article.

4

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.

Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, Feng G, Ying K, Zhuang W, Zhou J, Wu J, Leaw SJ, Zhang J, Lin X, Liang L, Yang N. Wang J, et al. Among authors: liang l. JAMA Oncol. 2021 May 1;7(5):709-717. doi: 10.1001/jamaoncol.2021.0366. JAMA Oncol. 2021. PMID: 33792623 Free PMC article. Clinical Trial.

5

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.

Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, Ma Z, Li X, Zhuang W, Liu Y, Li W, Cui J, Wang D, Liao W, Zhou J, Wang Z, Sun Y, Qiu X, Gao J, Bao Y, Liang L, Wang M. Lu S, et al. Among authors: liang l. J Thorac Oncol. 2021 Sep;16(9):1512-1522. doi: 10.1016/j.jtho.2021.05.005. Epub 2021 May 23. J Thorac Oncol. 2021. PMID: 34033975 Free article. Clinical Trial.

6

[Efficacy and safety of anti-PD-1 monoclonal antibody in advanced hepatocellular carcinoma after TACE combined with TKI therapy].

Xu ZN, Huang JJ, Zhou J, Huang WS, Guo YJ, Cai MY, Zhou JW, Lin LT, Liang LC, Zhu KS. Xu ZN, et al. Among authors: liang lc. Zhonghua Nei Ke Za Zhi. 2021 Jul 1;60(7):630-636. doi: 10.3760/cma.j.cn112138-20200928-00841. Zhonghua Nei Ke Za Zhi. 2021. PMID: 34619840 Chinese.

7

Comparison of the Value of Multiple Preoperative Objective Nutritional Indices for the Evaluation of Prognosis after Hepatectomy for Hepatocellular Carcinoma.

Qian W, Xiao-Jian J, Jun H, Liang L, Xiao-Yong C. Qian W, et al. Among authors: liang l. Nutr Cancer. 2022;74(9):3217-3227. doi: 10.1080/01635581.2022.2069276. Epub 2022 May 9. Nutr Cancer. 2022. PMID: 35533004

8

LPCAT1 enhances the invasion and migration in gastric cancer: Based on computational biology methods and in vitro experiments.

Chen ZX, Liang L, Huang HQ, Li JD, He RQ, Huang ZG, Song R, Chen G, Li JJ, Cai ZW, Huang JA. Chen ZX, et al. Among authors: liang l. Cancer Med. 2023 Jun;12(12):13438-13454. doi: 10.1002/cam4.5991. Epub 2023 May 15. Cancer Med. 2023. PMID: 37184260 Free PMC article.

9

The Impact of Growth Hormone Treatment on COVID-19 Susceptibility and Severity in Children with Short Stature: A Survey Study with Mendelian Randomization Analysis.

Qiu W, Wang R, Liang L, Sun Y, Zhou R, Wang X, Sun W, Gu X. Qiu W, et al. Among authors: liang l. Infect Drug Resist. 2024 Dec 20;17:5675-5684. doi: 10.2147/IDR.S483477. eCollection 2024. Infect Drug Resist. 2024. PMID: 39720618 Free PMC article.

10

Influence of remnant lipoprotein particle cholesterol on non-target lesions progression in patients undergoing percutaneous coronary intervention.

Liu J, Teng TQ, Li Z, Hu FW, Sha WW, Shen CX, Xia Y, Zhang YJ, Liang L. Liu J, et al. Among authors: liang l. Front Cardiovasc Med. 2024 Dec 10;11:1471479. doi: 10.3389/fcvm.2024.1471479. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39720212 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,092 results

Search Page

Filters